Cargando…

Unrecognized Kinetics of Serum Testosterone: Impact on Short-Term Androgen Deprivation Therapy for Prostate Cancer

PURPOSE: To evaluate the kinetics of serum testosterone (T) recovery following short-term androgen deprivation therapy (ADT), as the understanding thereof is essential for the proper management of prostate cancer (PCa), especially intermittent ADT. MATERIALS AND METHODS: This prospective analysis in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koo, Kyo Chul, Lee, Dong Hoon, Kim, Kyu Hyun, Lee, Seung Hwan, Hong, Chang Hee, Hong, Sung Joon, Chung, Byung Ha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990065/ https://www.ncbi.nlm.nih.gov/pubmed/24719121 http://dx.doi.org/10.3349/ymj.2014.55.3.570

Ejemplares similares

Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer
por: Hah, Yoon Soo, et al.
Publicado: (2019)

Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
por: Ahn, Hyun Kyu, et al.
Publicado: (2020)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
por: Nam, Wook, et al.
Publicado: (2018)

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis
por: Kim, Do Kyung, et al.
Publicado: (2019)

Can microfocal prostate cancer be regarded as low-risk prostate cancer?
por: Lee, Seung Hwan, et al.
Publicado: (2013)

Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer
por: Lee, Seung Hwan, et al.
Publicado: (2015)

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy
por: Heo, Ji Eun, et al.
Publicado: (2018)

Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer
por: Delgado, Jessica, et al.
Publicado: (2022)

Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring
por: Lee, Dong Hoon, et al.
Publicado: (2014)

Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy
por: Christie, David R.H., et al.
Publicado: (2021)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

A Novel Liver-targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men With Prostate Cancer
por: Rhee, Handoo, et al.
Publicado: (2021)

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model
por: Borque-Fernando, Ángel, et al.
Publicado: (2023)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ≥70 years
por: Koo, Kyo Chul, et al.
Publicado: (2014)

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
por: Cabarkapa, Sonja, et al.
Publicado: (2018)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
por: Wang, Yue, et al.
Publicado: (2017)

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
por: Choi, Hoon, et al.
Publicado: (2016)

The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer
por: Choi, Se Young, et al.
Publicado: (2021)

Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy
por: Sarkar, Arjun, et al.
Publicado: (2021)

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
por: Eom, Keun-Yong, et al.
Publicado: (2014)

Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone
por: Salciccia, Stefano, et al.
Publicado: (2020)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2021)

Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy
por: Lee, Kwang Suk, et al.
Publicado: (2017)

Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels
por: Koo, Kyo Chul, et al.
Publicado: (2015)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
por: Bang, Woo Jin, et al.
Publicado: (2022)

Comparison of the delta neutrophil index with procalcitonin, erythrocyte sedimentation rate, and C-reactive protein as predictors of sepsis in patients with acute prostatitis
por: Ahn, Hyun Kyu, et al.
Publicado: (2018)

Androgen Deprivation Therapy in Patients with Prostate Cancer is Associated with the Risk of Subsequent Alzheimer's Disease but Not with Vascular Dementia
por: Kim, Jong Won, et al.
Publicado: (2022)

Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation
por: Aversa, Antonio, et al.
Publicado: (2012)

Stauntonia hexaphylla Extract Ameliorates Androgenic Alopecia by Inhibiting Androgen Signaling in Testosterone-induced Alopecia Mice
por: Hong, Geum-Lan, et al.
Publicado: (2023)

Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer
por: Jung, Jaeyoon, et al.
Publicado: (2015)

Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2015)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
por: You, Dalsan, et al.
Publicado: (2015)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_gmegesomfnf2kr3g1g2cmha7b5